24.21
-1.91 (-7.31%)
| Previous Close | 26.12 |
| Open | 26.01 |
| Volume | 2,296,870 |
| Avg. Volume (3M) | 1,635,184 |
| Market Cap | 4,471,334,400 |
| Price / Earnings (Forward) | 81.30 |
| Price / Sales | 5.61 |
| Price / Book | 5.06 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Braidwell Lp | 30 Sep 2025 | 1,826,155 |
| Matthews International Capital Management Llc | 30 Sep 2025 | 1,028,447 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 90.00 (Barclays, 271.75%) | Buy |
| Median | 74.50 (207.72%) | |
| Low | 48.00 (UBS, 98.27%) | Buy |
| Average | 70.50 (191.20%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 30.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| UBS | 08 Dec 2025 | 48.00 (98.27%) | Buy | 26.12 |
| Barclays | 13 Nov 2025 | 90.00 (271.75%) | Buy | 31.01 |
| Cantor Fitzgerald | 13 Nov 2025 | 75.00 (209.79%) | Buy | 31.01 |
| RBC Capital | 13 Nov 2025 | 74.00 (205.66%) | Buy | 31.01 |
| HC Wainwright & Co. | 17 Oct 2025 | 60.00 (147.83%) | Buy | 31.96 |
| JP Morgan | 09 Oct 2025 | 76.00 (213.92%) | Buy | 32.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Dec 2025 | Announcement | Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 |
| 27 Nov 2025 | Announcement | Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade |
| 13 Nov 2025 | Announcement | Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia |
| 12 Nov 2025 | Announcement | Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights |
| 03 Nov 2025 | Announcement | Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting |
| 29 Oct 2025 | Announcement | Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results |
| 14 Oct 2025 | Announcement | Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |